So far, HER2-targeting CAR T cells exhibited persistent anti-tumor activity in vitro and in vivo [110], and various phase I studies evaluate HER2-directed CAR T cells for solid tumors, including gastric cancer (see Table 3). The gene discussed is ERBB2; the disease is gastric cancer.